e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Pharmacological treatment in primary care
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy and tolerability of ciclesonide (CIC) in the treatment of 24,037 asthmatic patients in routine clinical care
C. F. Vogelmeier, T. Hering, P. Sander, T. D. Bethke (Marburg, Berlin, Konstanz, Germany)
Source:
Annual Congress 2010 - Pharmacological treatment in primary care
Session:
Pharmacological treatment in primary care
Session type:
Thematic Poster Session
Number:
856
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. F. Vogelmeier, T. Hering, P. Sander, T. D. Bethke (Marburg, Berlin, Konstanz, Germany). Efficacy and tolerability of ciclesonide (CIC) in the treatment of 24,037 asthmatic patients in routine clinical care. Eur Respir J 2010; 36: Suppl. 54, 856
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
Related content which might interest you:
Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012
Efficacy of the using budesonide/formoterol in patients with bronchial asthma (BA): the study of routine clinical practice
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006
Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
Clinical benefits and safety of long term treatment with montelukast (M) in patients with mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 261s
Year: 2001
Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52 week long study
Source: Eur Respir J 2002; 20: Suppl. 38, 373s
Year: 2002
Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
Safety profile of tiotropium add-on therapy in paediatric patients by gender
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018
A post-marketing study to evaluate the safety and tolerability of a non-chlorofluorocarbon salbutamol inhaler in asthmatic patients in general practice
Source: Eur Respir J 2002; 20: Suppl. 38, 78s
Year: 2002
Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Safety and tolerability of indacaterol over 52 weeks of treatment in COPD
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
Safety and tolerability of multiple-dose indacaterol, a novel 24-hour β
2
-agonist, in patients with mild asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 253s
Year: 2005
Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Efficacy and safety of nintedanib in the elderly patient with IPF
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Efficacy and safety of long-term therapy with Salamol combined with Beclason
versus
Salamol only in patients with mild persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002
Clinical efficacy and patients‘ satisfaction for 100 consequent COPD patients using tiotropium respimat
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept